Tekmira Provides Periodic Update on TKM-Ebola Program
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- US stock futures steady after tech slump; investors focus on Middle East tensions
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- U.S. debt tops $40 trillion
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Marvell shares jump after giving Google warrants amid custom chip deal
Tekmira Pharma (TKMR) Commences Limited GMP Manufacture of Guinea-Variant Ebola Therapeutic
October 22, 2014 6:29 AM EDTTekmira Pharma (Nasdaq: TKMR) provides an update on its Ebola program. The Company is reporting it has commenced limited GMP manufacture of a new therapeutic specifically targeting the Ebola Guinea variant, which is the viral variant responsible for the Ebola epidemic currently prevalent in West Africa. Supply of this new product will be available in early December, 2014, for potential use by various collaborators. As definitive agreements are established we will provide updates accordingly.
The genomic sequence of the Ebola virus responsible for the current outbreak in West Africa has been determined from several... More
